Medications development for the treatment of pregnant addicts and their infants

LDR 01901nam a2200433 a 4500
001 003562363
003 MiAaHDL
005 20221205000000.0
006 m d
007 cr bn ---auaua
008 010924s1995 mdua b f000 0 eng d
010 ‡a96197033
016 7 ‡a9608521 ‡2DNLM
035 ‡a(MiU)990035623630106381
035 ‡asdr-miu.990035623630106381
035 ‡z(MiU)MIU01000000000000003562363-goog
035 ‡a(OCoLC)32648176
035 ‡z(MiU)Aleph003562363
040 ‡aNbU-M ‡cDLC ‡dNLM ‡dIHS ‡dGZM ‡dOCL ‡dEYM
050 0 4 ‡aRG580.D76 ‡bM43 1995
060 1 0 ‡aWM 270 ‡bM4899 1995
060 0 0 ‡aW1 ‡bNA486Q no.149 1995
245 0 0 ‡aMedications development for the treatment of pregnant addicts and their infants / ‡ceditors, C. Nora Chiang, Loretta P. Finnegan.
260 ‡aRockville, Md. : ‡bU.S. Dept. of Health and Human Services, Public Health Service, National Institute of Health, National Institute on Drug Abuse, ‡c1995.
300 ‡aiv, 246 p. : ‡bill. ; ‡c23 cm.
490 0 ‡aNIH publication ; ‡vno. 95-3891
490 0 ‡aNIDA research monograph ; ‡v149
500 ‡a"Based on the papers from a technical review on M̀edications Development for the Treatment of Pregnant Addicts and Their Infants' held on August 26-27, 1993."--p. ii.
504 ‡aIncludes bibliographical references.
538 ‡aMode of access: Internet.
650 2 2 ‡aPrenatal Exposure Delayed Effects ‡vcongresses.
650 2 2 ‡aDrug Evaluation ‡vCongresses.
650 2 2 ‡aSubstance-Related Disorders ‡xdrug therapy ‡vCongresses.
650 1 2 ‡aSubstance-Related Disorders ‡xPregnancy ‡vCongresses.
650 0 ‡aPregnant women ‡xDrug use.
650 0 ‡aNewborn infants ‡xDiseases.
650 0 ‡aDrug abuse in pregnancy.
700 1 ‡aFinnegan, Loretta P.
700 1 ‡aChiang, C. Nora.
710 2 ‡aNational Institute on Drug Abuse.
899 ‡a39015050822330
CID ‡a003562363
DAT 0 ‡a20010924000000.0 ‡b20221205000000.0
DAT 1 ‡a20221208060740.0 ‡b2023-06-26T18:22:30Z
CAT ‡aSDR-MIU ‡cmiu ‡dALMA ‡lprepare.pl-004-008
FMT ‡aBK
HOL ‡0sdr-miu.990035623630106381 ‡aMiU ‡bSDR ‡cMIU ‡f003562363 ‡pmdp.39015050822330 ‡sMIU ‡1990035623630106381
974 ‡bMIU ‡cMIU ‡d20230626 ‡sgoogle ‡umdp.39015050822330 ‡y1995 ‡rpd ‡qbib ‡tUS fed doc